Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	12/1/2011
Gender:	Male
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication

ARUP test code 2012015

Skeletal Dysplasia Panel Specimen	Whole Blood

Skeletal Dysplasia Panel Interp

Positive

RESULT
One pathogenic variant was detected in the COL1A1 gene. One variant of uncertain significance was detected in the FLNB gene.

PATHOGENIC VARIANT
Gene: COL1A1 (NM_000088.4)
Nucleic Acid Change: c.1243C>T; Heterozygous
Amino Acid Alteration: p.Arg415Ter
Inheritance: Autosomal Dominant

VARIANT OF UNCERTAIN SIGNIFICANCE
Gene: FLNB (NM_001164317.2)
Nucleic Acid Change: c.4483+2T>C; Heterozygous
Inheritance: Autosomal Dominant and Recessive

INTERPRETATION
One pathogenic variant, c.1243C>T; p.Arg415Ter, was detected in the COL1A1 gene by massively parallel sequencing. Pathogenic germline COL1A1 variants are inherited in an autosomal dominant manner, and are associated with both skeletal and/or aortopathy disorders including: osteogenesis imperfecta type I (MIM: 166200), osteogenesis imperfecta type II (MIM: 166210), osteogenesis imperfecta type III (MIM: 259420), osteogenesis imperfecta type IV (MIM: 166220), arthrochalasia type Ehlers-Danlos syndrome 1 (MIM: 130060) and combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1 (MIM: 619115, OMIM(R)). This result is consistent with a diagnosis of COL1A1-related skeletal and/or aortopathy disorder. This individual's future offspring have a 50 percent chance of inheriting the pathogenic variant.

One variant of uncertain clinical significance, c.4483+2T>C, was detected in the FLNB gene by massively parallel sequencing. Pathogenic variants in FLNB are associated with autosomal dominant atelosteogenesis, type I (MIM: 108720) and type III (MIM: 108721), Boomerang dysplasia (MIM: 112310), and Larsen syndrome (MIM: 150250) as well as with autosomal recessive spondylocarpotarsal synostosis syndrome (MIM: 272460, OMIM(R)). However, it is uncertain whether this variant is disease-associated or benign.

Please refer to the background information included in this report for a list of the genes analyzed, methodology, and limitations of this test.

H=High, L=Low, *=Abnormal, C=Critical

Evidence for variant classification:
The COL1A1 c.1243C>T; p.Arg415Ter variant (rs72648326, ClinVar Variation ID 425597) is reported in the literature in multiple individuals affected with osteogenesis imperfecta (Higuchi 2021, Holtz 2023, Hruskova 2016, Ju 2020, Li 2019, Li 2023, Lin 2024, Lindahl 2015, MacCarrick 2024, Mei 2022, Nadyrshina 2012, Ohata 2020, Panigrahi 2020, Reis 2005, Ries-Levavi 2024, Takeda 2022, Willing 1996, Zhang 2016, Zhytnik 2019, Zhytnik 2020) and one individual with Ehlers-Danlo syndrome (Morlino 2020). This variant is absent from the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. This variant induces an early termination codon and is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic.

The FLNB c.4483+2T>C variant (rs373720589) is found in an alternative transcript and, to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID: 252547). This variant is found in the African/African American population with an allele frequency of 0.441% (72/16312 alleles) in the Genome Aggregation Database (v2.1.1). This variant disrupts the canonical splice donor site of intron 26. However, exon 25 of NM_001164317.2 is not included on all transcript isoforms of FLNB (including NM_001457), and thus this impact of this variant on overall gene function is not clear. While the high population frequency suggests that this is likely a benign variant, given the lack of clinical and functional data, the significance of this variant is uncertain at this time.

RECOMMENDATIONS
Medical screening and management should rely on clinical findings and family history. Genetic consultation is recommended. At-risk family members should be offered testing for the identified pathogenic COL1A1 variant (Familial Targeted Sequencing, ARUP test code 3005867). Because parental somatic or germline mosaicism for the identified COL1A1 pathogenic variant cannot be excluded, this individual's parents should be offered prenatal diagnosis in future pregnancies. Surveillance of the literature for new information concerning the uncertain variant is recommended.

COMMENTS
Likely benign and benign variants are not reported.
Variants in the following region(s) may not be detected by NGS with sufficient confidence in this sample due to technical limitations: None

REFERENCES
Higuchi Y et al. Genetic analysis in Japanese patients with osteogenesis imperfecta: Genotype and phenotype spectra in 96 probands. Mol Genet Genomic Med. 2021 Jun;9(6):e1675. PMID: 33939306.
Holtz AP et al. Genetic analysis of osteogenesis imperfecta in a large Brazilian cohort. Bone. 2023 Apr;169:116683. PMID: 36709916.
Hruskova L et al. Eight mutations including 5 novel ones in the COL1A1 gene in Czech patients with osteogenesis imperfecta. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Sep;160(3):442-7. PMID: 27132807.
Ju M et al. Mutation spectrum of COL1A1/COL1A2 screening by high-resolution melting analysis of Chinese patients with osteogenesis imperfecta. J Bone Miner Metab. 2020 Mar;38(2):188-197. PMID: 31414283.
Li L et al. Genotypic and phenotypic characterization of Chinese patients with osteogenesis imperfecta. Hum Mutat. 2019 May;40(5):588-600. PMID: 30715774.
Li S et al. Clinical and genetic profiles of 985 Chinese families with skeletal dysplasia. Chin Med J (Engl). 2023 Jun 20;136(12):1485-1487. PMID: 37334733.
Lin X et al. Genotype-phenotype relationship and comparison between eastern and western patients with osteogenesis

imperfecta. J Endocrinol Invest. 2024 Jan;47(1):67-77. PMID: 37270749.
Lindahl K et al. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015 Aug;23(8):1042-50. PMID: 25944380.
MacCarrick G et al. Clinical utility of comprehensive gene panel testing for common and rare causes of skeletal dysplasia and other skeletal disorders: Results from the largest cohort to date. Am J Med Genet A. 2024 Sep;194(9):e63646. PMID: 38702915.
Mei Y et al. Comparing Clinical and Genetic Characteristics of De Novo and Inherited COL1A1/COL1A2 Variants in a Large Chinese Cohort of Osteogenesis Imperfecta. Front Endocrinol (Lausanne). 2022 Jul 14;13:935905. PMID: 35909573.
Morlino S et al. COL1-related overlap disorder: A novel connective tissue disorder incorporating the osteogenesis imperfecta/Ehlers-Danlos syndrome overlap. Clin Genet. 2020 Mar;97(3):396-406. PMID: 31794058.
Nadyrshina DD et al. Studies of type I collagen (COL1A1) alpha1 chain in patients with osteogenesis imperfecta. Genetika. 2012 Mar;48(3):372-80. Russian. PMID: 22679784.
Ohata Y et al. Comprehensive genetic analyses using targeted next-generation sequencing and genotype-phenotype correlations in 53 Japanese patients with osteogenesis imperfecta. Osteoporos Int. 2019 Nov;30(11):2333-2342. Epub 2019 Jul 29. Erratum in: Osteoporos Int. 2020 Jun;31(6):1185. PMID: 31363794.
OMIM(R) Copyright (C) 1996 - Present year, Johns Hopkins University All rights reserved.
Panigrahi I et al. Over-Representation of Recessive Osteogenesis Imperfecta in Asian Indian Children. J Pediatr Genet. 2020 Sep 16;11(1):81-86. PMID: 35186396.
Reis FC et al. Molecular findings in Brazilian patients with osteogenesis imperfecta. J Appl Genet. 2005;46(1):105-8. PMID: 15741671.
Ries-Levavi L et al. Genetic and biochemical analyses of Israeli osteogenesis imperfecta patients. Hum Mutat. 2004 Apr;23(4):399-400. PMID: 15024745.
Takeda R et al. Clinical and molecular features of patients with COL1-related disorders: Implications for the wider spectrum and the risk of vascular complications. Am J Med Genet A. 2022 Sep;188(9):2560-2575. PMID: 35822426.
Willing MC et al. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996 Oct;59(4):799-809. PMID: 8808594.
Zhang H et al. Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61 Chinese patients with osteogenesis imperfecta. Mol Med Rep. 2016 Nov;14(5):4918-4926. PMID: 27748872.
Zhytnik L et al. COL1A1/2 Pathogenic Variants and Phenotype Characteristics in Ukrainian Osteogenesis Imperfecta Patients. Front Genet. 2019 Aug 9;10:722. PMID: 31447884.
Zhytnik L et al. Inter- and Intrafamilial Phenotypic Variability in Individuals with Collagen-Related Osteogenesis Imperfecta. Clin Transl Sci. 2020 Sep;13(5):960-971. PMID: 32166892

This result has been reviewed and approved by [redacted]
BACKGROUND INFORMATION: Skeletal Dysplasia Panel, Sequencing and Deletion/Duplication
CHARACTERISTICS: Skeletal dysplasias are a heterogeneous group of more than 400 disorders characterized by abnormal growth of cartilage or bone. Clinical features may include shortening, bowing, fracturing, thinning, thickening, or under mineralization of the bones; abnormal ribs; small chest circumference; and extra fingers or toes. Some disorders may be detectable prenatally, while others are not identified until birth or later childhood.

EPIDEMIOLOGY: Collective incidence of 1 in 5000

CAUSE: Pathogenic germline variants in genes associated with cartilage and bone growth

H=High, L=Low, *=Abnormal, C=Critical

INHERITANCE: Contingent on etiology; autosomal recessive, autosomal dominant, and X-linked inheritance, depending on the causative gene

CLINICAL SENSITIVITY: Dependent on the specific skeletal dysplasia; 99 percent for achondroplasia and thanatophoric dysplasia; greater than 95 percent for COL1A1/2 osteogenesis imperfecta; greater than 90 percent for achondrogenesis type 1B, diastrophic dysplasia, and campomelic dysplasia.

GENES TESTED: AGPS, ALPL, ARSL, CANT1, CCN6, CILK1, COL1A1, COL1A2,* COL2A1, COL10A1, COL11A1, COL11A2, COMP, CRTAP, DDR2, DLL3, DYM,* DYNC2H1, EBP, EVC,* EVC2, FGFR1,* FGFR2, FGFR3, FKBP10, FLNA, FLNB, GDF5, GNPAT, HSPG2, IFT80, INPPL1, LBR, LIFR, NEK1,* NPR2, P3H1, PCNT, PEX7, POR,* PPIB, PTH1R, RUNX2, SERPINH1, SLC26A2, SLC35D1, SMARCAL1, SOX9, TRIP11, TRPV4, TTC21B, WDR19, WDR35
*One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see limitations section below.

METHODOLOGY: Probe hybridization-based capture of all coding exons and exon-intron junctions of the targeted genes, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and to confirm reported variants that do not meet acceptable quality metrics. A proprietary bioinformatic algorithm was used to detect large (single exon-level or larger) deletions or duplications in the indicated genes. Large deletions/duplications confirmed using an orthogonal exon-level microarray. Human genome build 19 (Hg 19) was used for data analysis.

ANALYTICAL SENSITIVITY: The analytical sensitivity is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions (indels) from 1-10 base pairs in size. Indels greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced. Deletions of 2 exons or larger are detected with sensitivity greater than 97 percent; single exon deletions are detected with 62 percent sensitivity. Duplications of 3 exons or larger are detected at greater than 83 percent sensitivity. Specificity is greater than 99.9 percent for all variant classes.

LIMITATIONS: A negative result does not exclude diagnosis of a skeletal dysplasia. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Variants in the chr17:70,119,704-70,119,743 region of SOX9 exon 3 may not be detected. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Regulatory region variants and deep intronic variants will not be identified, including deletions/duplications in the upstream regulatory region of SOX9. Precise breakpoints for large deletions or duplications are not determined in this assay and single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement. The actual breakpoints for the deletion or duplication may extend beyond or be within the exon(s) reported. This test is not intended to detect duplications of 2 or fewer exons in size, though these may be identified. Single exon deletions are reported but called at a lower sensitivity. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA (mtDNA) mutations, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed.

The following regions are not sequenced due to technical limitations of the assay:
EVC(NM_153717) exon(s) 1

Single exon deletions/duplications will not be called for the following exons:
COL1A2(NM_000089) 3; EVC (NM_153717) 1; EVC(NM_001306090) 1; EVC(NM_001306092) 1;
FGFR1(NM_001354367) 18; FGFR1(NM_001354369) 18;
FGFR1(NM_001354370) 17; DYM(NM_001353212) 14; DYM(NM_001353213) 14; DYM(NM_001353214) 14; DYM(NM_001353215) 14;
DYM(NM_001374428) 15; DYM(NM_001374429) 14; DYM(NM_001374430) 14 18; DYM(NM_001374431) 14; DYM(NM_001374432) 13;
DYM(NM_001374433) 17; DYM(NM_001374441) 9; NEK1(NM_001374422) 17; NEK1(NM_001374423) 16; POR (NM_001382655) 3

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Skeletal Dysplasia Panel Specimen	24-347-402504	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Skeletal Dysplasia Panel Interp	24-347-402504	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical